Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.61 USD | +1.44% | +4.40% | 0.00% |
05-08 | ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | HC Wainwright Initiates ArriVent BioPharma With Buy Rating, $25 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 581M 46.43B |
---|---|---|---|---|---|
Net income 2024 * | -80M -6.39B | Net income 2025 * | -90M -7.19B | EV / Sales 2024 * | - |
Net cash position 2024 * | 193M 15.39B | Net cash position 2025 * | 481M 38.4B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.93
x | P/E ratio 2025 * |
-6.57
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.32% |
1 day | +1.44% | ||
1 week | +4.40% | ||
Current month | +6.17% | ||
1 month | +1.21% | ||
3 months | -16.52% |
Date | Price | Change | Volume |
---|---|---|---|
09/05/24 | 17.54 | +1.04% | 8 223 |
08/05/24 | 17.36 | +0.64% | 40,811 |
07/05/24 | 17.25 | +0.06% | 41,505 |
06/05/24 | 17.24 | +0.06% | 25,226 |
03/05/24 | 17.23 | +2.56% | 23,943 |
Delayed Quote Nasdaq, May 09, 2024 at 08:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 581M | |
+24.22% | 46.71B | |
+48.83% | 41.8B | |
-1.02% | 41.52B | |
-5.86% | 29.55B | |
+11.15% | 25.78B | |
-20.97% | 19.26B | |
+2.91% | 12.14B | |
-2.38% | 12.08B | |
+30.30% | 11.98B |
- Stock Market
- Equities
- AVBP Stock